CAJ | 학술논문

心肌梗死期间死亡的心肌细胞将由没有收缩功能的疤痕组织替代,因而极可能引起心力衰竭.对治疗心衰来说,修复死亡或损伤的心肌以及改善心功能仍面临着极大挑战.干细胞移植已在近年来的实验中用于修复损失的心肌.本文总结了近期在心肌损伤动物中实施胚胎干细胞移植的实验结果,并着重介绍对这类特定细胞的研究进展.胚胎干细胞取源于早期哺乳类胚胎的胚芽细胞,属于多功能干细胞.这类细胞具有长期增殖而不分化的能力,或能够在培养过程中分化成包括心肌细胞在内的所有特殊体细胞.由于胚胎干细胞具有极大的增殖和分化为成熟组织的能力,它们可能成为一种潜在的很有实用价值的细胞来源,可用于对病态心脏的功能心肌再生的细胞治疗.新近的研究表明,在心肌梗死动物模型中,心肌内移植胚胎干细胞或由其分化成的心肌样细胞,能导致已损伤心肌的再生,并改善心脏功能.另外,在病毒性心肌炎小鼠中,静脉输入胚胎干细胞可明显提高生存率和减轻心肌损伤.有关人类胚胎干细胞在体外分化成心肌细胞以及这些细胞的特性,近来已有报道.然而,要在临床能应用人类胚胎干细胞或由其分化成的心肌细胞来治疗晚期心脏疾病,还必须越过大量的伦理、法律和科学上的障碍.
심기경사기간사망적심기세포장유몰유수축공능적파흔조직체대,인이겁가능인기심력쇠갈.대치료심쇠래설,수복사망혹손상적심기이급개선심공능잉면림착겁대도전.간세포이식이재근년래적실험중용우수복손실적심기.본문총결료근기재심기손상동물중실시배태간세포이식적실험결과,병착중개소대저류특정세포적연구진전.배태간세포취원우조기포유류배태적배아세포,속우다공능간세포.저류세포구유장기증식이불분화적능력,혹능구재배양과정중분화성포괄심기세포재내적소유특수체세포.유우배태간세포구유겁대적증식화분화위성숙조직적능력,타문가능성위일충잠재적흔유실용개치적세포래원,가용우대병태심장적공능심기재생적세포치료.신근적연구표명,재심기경사동물모형중,심기내이식배태간세포혹유기분화성적심기양세포,능도치이손상심기적재생,병개선심장공능.령외,재병독성심기염소서중,정맥수입배태간세포가명현제고생존솔화감경심기손상.유관인류배태간세포재체외분화성심기세포이급저사세포적특성,근래이유보도.연이,요재림상능응용인류배태간세포혹유기분화성적심기세포래치료만기심장질병,환필수월과대량적윤리、법률화과학상적장애.
Cardiomyocytes deceased during myocardial infarction (MI) are replaced with non-contractile scar tissue, which has a great chance to cause heart failure. Repair of dead or injured myocardium and improvement of cardiac function remain a serious challenge for the therapy of heart failure. Recently, stem cells have been transplanted in experimental settings to replace lost myocardium. This article summarizes the recent experimental findings on transplantation of embryonic stem cells (ESCs) and their derived cells in animals with myocardial injury and highlights the progresses in research of these particular cell types. Beneficial effects of cell transplantation with other cell types in injured hearts have been detailed in other reviews.ESCs are pluripotent cells derived from early mammalian embryos at the blasto-stage. These cells have the capacity for prolonged undifferentiated proliferation or differentiation into all of specialized somatic cell types of the body in culture, including cardiomyocytes. Because of the great ability of proliferation and differentiation to mature tissues, ESCs are a potential valuable resource for cell therapy targeting regeneration of functional myocardium in diseased hearts. In recent animal studies intramyocardial transplantation of ESCs or their differentiated cardiac-like cells regenerated injured myocardium and improved heart function in infarcted animal models. In addition, intravenous infusion of ESCs significantly increased the survival rate and attenuated myocardial injury in viral myocarditic mice. Development and characterization of cardiomyocytes in vitro from human ESCs have been reported recently. However, many ethical, political, and scientific barriers have to be overcome before clinical utilization of human ESCs and their differentiated cells for treating end-stage cardiac diseases.